CRC 12090: An Open-Label Randomized Phase III Trial of BMS-936558 Versus Docetaxel in Previously Treated Metastatic Non-Squamous Cell Non-small Cell Lung Cancer (NSCLC)
- Type of Study
- Cancer (Oncology) - Lung
- Location
- Swedish Cancer Institute
- Short Description
Purpose: The purpose of the study is to compare the overall survival of BMS-936558 as compared with Docetaxel in subjects with non-squamous cell non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy.
- Status
- Open to Enrollment
- Principal Investigator
- Howard (Jack) West, M.D.
- Eligibility Notes
• Subjects with histologically or cytologically-documented locally advanced non-squamous cell NSCLC who present with Stage IIIB/IV disease or recurrent disease following radiation therapy or surgical resection
• Disease recurrence or progression during/after one prior platinum-containing doublet chemotherapy regimen for advanced or metastatic disease
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
• No subjects with carcinomatous meningitis
• No subjects with active, known or suspected autoimmune disease, or subjects with interstitial lung disease
• No Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of randomization
• No prior therapy with anti-programmed death-1 (anti-PD-1), anti programmed cell death ligand 1 (anti-PD-L1), anti programmed cell death ligand 2 (anti-PD-L2), anti-CD137, or anti Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4) antibody (including Ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
• No prior treatment with Docetaxel- More Info Link
- Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
- Phone
- (206) 215-3086
- CancerResearch@swedish.org
